BCL2 and lung cancer: Collectively, these data suggest that IL2–STAT5 pathway activity can predict cellular sensitivity to Bcl-2 inhibitors in lung cancer with higher specificity and sensitivity than evaluating single genes in the Bcl-2 family alone.